Almirall

Trending Articles

  1. From RAGs to riches: AI in pharma Mirit Eldor, Managing Director, Life Sciences Solutions at Elsevier, reflects on the growth and future of AI in the pharmaceutical industry
  2. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  3. Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its...
  4. Neuraxpharm bolsters its CNS-targeting therapeutic range with narcolepsy drugs Nuvigil and Provigil By acquiring Teva Pharmaceutical's Nuvigil and Provigil, Neuraxpharm hopes to enhance its narcolepsy offering, while also expanding its global presence
  5. NMD Pharma's drug candidate for Charcot-Marie-Tooth disease granted ODD by the FDA The small molecule CIC-1 inhibitor will be used to treat CMT, which currently has no approved treatments

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Research & Development

AI in pharma: enhancing the drug development process

AI and advanced analytics can help to enhance R&D productivity, speed of drug commercialisation and provide access to quality data
Regulatory

Anti-IL-21 monoclonal antibody licensed by Almirall

NN-8828, the IL-21 blocker, is exclusively owned by Almirall and will be used to treat immune inflammatory dermatological diseases
Sustainability

Almirall receives an 'A' rating by CDP

Almirall achieved an ‘A’ for its Climate Change mitigation measures and a ‘B’ for its Management of water securit
Research & Development

Almirall and etherna to develop mRNA-based therapies in medical dermatology

The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Research & Development

Almirall, Barcelona Supercomputing Center and Nostrum Biodiscovery collaborate to find AI-based therapies

The partnership aims to improve the design of protein-protein modulators through artificial intelligence to identify new therapeutic approaches for the treatment of skin diseases
Research & Development

Almirall and Absci announce AI drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases
Manufacturing

Centrient opens dedicated innovation lab at Almirall’s R&D centre

The two companies have entered into an agreement whereby Centrient will open a new dedicated innovation lab at Almirall’s R&D centre
Subscribe now